Watch CNTX. Know when insiders buy.
One email the day a filing lands. Free.
CNTX
Context Therapeutics Inc.
0.37
−0.00 −1.08%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
32
FLAG · shorts 32
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $33.6MP/E —DIV YIELD —FCF YIELD -101.19%REV TTM —NET INCOME −$46MNET CASH —52W 0.36 – 3.36SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$15M | −$14.6M | — | -0.15 | −$7M | $18K | −$7M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$9.3M | −$8.7M | — | -0.09 | −$11.4M | $37K | −$11.5M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.8M | −$13M | — | -0.14 | −$8.9M | $0 | −$8.9M | Mar 23 |
| Q3 2025 · Sep 30 | — | — | — | −$10.6M | −$9.7M | — | -0.10 | −$6.6M | $0 | −$6.6M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$9.8M | −$8.8M | — | -0.09 | −$5.8M | $0 | −$5.8M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$5.5M | −$4.6M | — | -0.05 | −$5M | $34K | −$5.1M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.3M | −$3.3M | — | 0.00 | −$4.9M | $0 | −$4.9M | Mar 23 |
| Q3 2024 · Sep 30 | — | — | — | −$18.7M | −$17.5M | — | -0.22 | −$1.9M | $7K | −$1.9M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$3.1M | −$2.3M | — | -0.04 | −$3.4M | $0 | −$3.4M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$3.8M | −$3.7M | — | -0.23 | −$4.4M | $0 | −$4.4M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.9M | −$6.8M | — | -0.42 | −$7.2M | $0 | −$7.2M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$6.2M | −$5.9M | — | -0.37 | −$3.5M | $0 | −$3.5M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$39.7M | −$36.1M | — | -0.38 | −$26.4M | $34K | −$26.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$29.9M | −$26.7M | — | -0.46 | −$14.6M | $7K | −$14.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$25.1M | −$24M | — | -1.50 | −$21M | $0 | −$21M | — | — |
| FY2022 · to Dec 31 | — | — | −$15.4M | −$14.8M | — | -0.93 | −$13.5M | $37K | −$13.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$10.5M | −$10.5M | — | -3.69 | −$8.8M | $0 | −$8.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$2.6M | $6.6M | — | -3.96 | −$1M | — | — | — | — |
Every number comes from Context Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.